Cancer Research UK Cambridge Centre

Charlotte led the Cambridge Breast IMRT Trial, providing evidence for simple breast IMRT as standard-of-care; and IMPORT Low, showing partial-breast radiotherapy was non-inferior to whole-breast with similar or reduced toxicity. She leads IMPORT High with 5-year results showing efficacy and safety of hypofractionated simultaneous integrated boost. Charlotte is a member of the FAST-Forward Trial Management Group, demonstrating that 1-week is non-inferior to 3-week radiotherapy with similar side-effects. These trials have informed NICE guidelines and are internationally practice-changing. She also leads PRIMETIME: biomarker-directed omission of breast radiotherapy; and PARABLE, the first UK breast proton beam therapy trial.

Charlotte facilitated international breast radiotherapy guidelines during COVID-19 pandemic and co-led UK and European Breast Radiotherapy Consensuses, facilitating equity of access to breast hypofractionation. She was awarded a NIHR Research Professorship and leads the Cancer Research UK RadNet Cambridge Radiation Research Centre of Excellence for translation of discovery science into patient benefit.

She was Editor-in-Chief of Clinical Oncology from 2015-21 and chaired the Lancet Breast Cancer Commission. In 2023, she was elected to the Academy of Medical Sciences and awarded the Royal College of Radiologist’s Gold Medal. Charlotte is passionate about implementing patient-centred research through team science and nurturing the next generation of researchers.